secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rafael Holdings, Inc. (RFL)
CIK:        0001713863
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001213900-24-052893
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rafael Holdings Q3 net loss $32.4M ($1.36/sh) vs $1.4M loss YoY; driven by $89.9M IPR&D expense
--------------------------------------------------------------------------------

- Net loss from continuing operations of $32.4M ($1.36 diluted EPS) compared to $1.4M ($0.06) in prior-year quarter.
- Q3 includes $89.9M in-process R&D expense from Cornerstone acquisition treatment, offset by $31.3M recovery of Cornerstone receivables.
- Cash and marketable securities $72.4M as of April 30, 2024.
- Increased Day Three Labs stake to 79% majority, began consolidating Jan 2024; Q3 R&D up to $1.5M from $0.7M.
- Cyclo Therapeutics investment recorded $4.4M unrealized loss in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1713863/000121390024052893/0001213900-24-052893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1713863/000121390024052893/ea0207870-8k_rafael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-052893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer